• Publications
  • Influence
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
This work presents a meta-analyses of the immune system’s response to chronic obstructive pulmonary disease and shows clear patterns of decline in the immune systems of elderly patients with compromised immune systems. Expand
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
This study highlights the need to understand more fully the role of Epstein-Barr virus in the development of central giant cell granuloma and its role in the immune system. Expand
Community-Acquired Pneumonia in Adults: Guidelines for Management
This guideline is to provide assistance to clinicians in the diagnosis and treatment of community-acquired pneumonia and includes use of laboratory criteria for diagnosis and approach to antimicrobial therapy. Expand
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults
It was decided that all of the information dealing with the initial empiric treatment regimens should be in tabular format with footnotes, and the topics selected for updating have been organized according to the headings used in the August 2000 CAP guidelines. Expand
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian
The Canadian CAP Working Group’s findings and recommendations will help improve the quality of care and reduce the number of adverse events in the care of severely ill patients. Expand
Fluoroquinolone Resistance in Clinical Isolates ofStreptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance
Isolates with intermediate-level and high-level resistance harbored substitutions of Phe and Tyr for Ser-79 or Asn and Ala for Asp-83 in ParC and an additional substitution in GyrA which included either Glu-85-Lys (Gly) or Ser-81-Phe (Tyr). Expand
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
Among the newer fluoroquinolones, clinically significant cardiac events are rare or absent but possible interactions in patients receiving other drugs capable of causing QT prolongation should be anticipated. Expand